



**Notification: 7501**

**Category**

**HCPCS - Drugs & Biologicals**

**Topic**

**Rituximab and its biosimilars – HCPCS codes J9312, Q5115, Q5119 and Q5123**

**What is changing? / Change Description:**

**We apply the following limitations for charges of HCPCS code J9312, Q5115, Q5119 and Q5123:**

- No more than 100 units every 2 weeks for the initial dose if billed with a diagnosis of rheumatoid arthritis or pemphigus vulgaris.**
- If billed with a diagnosis of rheumatoid arthritis, subsequent doses must be administered no more frequently than once every 24 weeks.**
- If billed with a diagnosis of pemphigus vulgaris, subsequent doses are limited to no more than 50 units dosed 12 months after the initial administration, followed by subsequent doses administered no more frequently than once every 6 months thereafter.**

**Language**

**English**

**Impacted Products**

**Medicaid – Louisiana**

**Why is Humana making this change? / Change Reason:**

**The above limitations are established according to the FDA approved package insert and prescribing information and pharmaceutical compendia.**